Merck press release
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced early components of a multi-faceted strategy to provide rapid, broad and sustainable access in low- and middle-income countries (LMICs) to alimatravir (MK-8527), an investigational, novel, once-monthly oral pill as PrEP for the prevention of HIV-1, following regulatory approval. Initial access plans as part of Merck’s broader strategy include establishing early generic licensing covering 129 LMICs; supporting targeted, regional manufacturing capabilities in Africa and Latin America; and investing early in product manufacturing to enable timely access and availability in regions of high unmet need. The first steps of this strategy are being announced in the lead up to the 26th International AIDS Conference in Rio de Janeiro, Brazil.
Read the full press release here.
SEE ALSO:
- Unitaid strengthens African manufacturing capacity for next-generation HIV prevention medicines
- AVAC and Access Bridge applaud monthly PrEP pill access announcement; call for speed, scale and equity in future monthly oral alimatravir introduction
Source : Merck
Related HIV and Co-Infections News
-
[AIDS 2026] [Press statement] Health GAP: Activists disrupt US Global AIDS Coordinator Jeff Graham at International AIDS Conference
-
[Report] Unitaid: Oil price shocks could raise the cost of HIV medicines by up to 44%
-
Unitaid invests an additional US$15 million to accelerate introduction, adoption and uptake of breakthrough HIV prevention products in diverse regions
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.